Study guide
12.2 Immunization Schedules, Vaccine Selection, and Travel Health
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
12.2 Immunization Schedules, Vaccine Selection, and Travel Health
Key Takeaways Explain This Topic AI
The National Advisory Committee on Immunization issues Canada's evidence-based vaccine recommendations, but each province and territory sets its own publicly funded schedule.
Live vaccines are contraindicated in pregnancy and in significant immunosuppression, and two live parenteral vaccines must be given on the same day or at least four weeks apart.
Recombinant zoster vaccine is a two-dose non-live series recommended for adults aged 50 and older, including those who previously had shingles or received the live vaccine.
Anaphylaxis to a previous dose or to a vaccine component is a true contraindication; a minor illness, a low-grade fever, or a family history of reaction is not.
Travel consultations should occur at least six weeks before departure, and yellow fever vaccine is only available from designated yellow fever vaccination centres.
Last updated: August 2026
12.2 Immunization Schedules, Vaccine Selection, and Travel Health
Exam Focus: The syllabus names "current childhood immunization schedules and vaccine administration issues in children" under special populations, and immunization appears again under health promotion. Expect contraindication screening, interval rules, and travel risk assessment.
How Canadian Immunization Is Governed
The National Advisory Committee on Immunization (NACI) provides Health Canada with independent, evidence-based recommendations, published in the Canadian Immunization Guide . NACI advises; it does not fund. Each province and territory decides which vaccines are publicly funded, for whom, and on what schedule. A vaccine can therefore be NACI-recommended and still be purchased privately in one province while free in another. Always confirm both the clinical recommendation and the local funding rule before advising a patient about cost.
Routine Childhood Immunization
Provincial schedules differ in detail but share a common architecture:
Age Typical antigens
2, 4, 6 months Diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type b (as a combined product); pneumococcal conjugate; rotavirus (oral); meningococcal C in some provinces
12 to 18 months Measles, mumps, rubella; varicella; pneumococcal conjugate booster; meningococcal C
4 to 6 years Diphtheria, tetanus, pertussis, polio booster; second measles-mumps-rubella or measles-mumps-rubella-varicella
- Grade 4 to 7 (school programs) Hepatitis B; human papillomavirus; meningococcal quadrivalent
- 14 to 16 years Tetanus, diphtheria, pertussis booster
Rotavirus vaccine is oral and live , and the first dose has an upper age limit because of intussusception risk, so late starts cannot simply be caught up.
Adults should receive a tetanus-diphtheria booster every 10 years with one adult dose containing pertussis, annual influenza vaccine from 6 months of age onward, COVID-19 vaccine as recommended each season, recombinant zoster vaccine as two doses from age 50, and pneumococcal vaccination as recommended for age and risk. Pregnant patients should receive influenza vaccine in any trimester and a pertussis-containing vaccine in every pregnancy to provide passive protection to the newborn.
Contraindications, Precautions, and False Contraindications
- True contraindication Applies to
- Anaphylaxis to a previous dose or a vaccine component That vaccine
Pregnancy Live vaccines (measles-mumps-rubella, varicella, live attenuated influenza, yellow fever with limited exceptions)
- Significant immunosuppression Live vaccines
- Encephalopathy within 7 days of a pertussis-containing vaccine Further pertussis-containing vaccines
Precautions (defer, weigh, or take extra care) include moderate to severe acute illness with fever, a history of Guillain-Barré syndrome within 6 weeks of a prior tetanus or influenza vaccine, and recent receipt of blood products, which can blunt the response to measles-containing and varicella vaccines.
False contraindications — these are not reasons to withhold a vaccine: mild illness with or without low-grade fever, current antibiotic therapy, prematurity, breastfeeding, a family history of adverse events, non-anaphylactic egg allergy for influenza vaccine, a prior local reaction, and stable neurological conditions.
Interval rules: inactivated vaccines may be given at any interval relative to each other and to live vaccines. Two live parenteral vaccines must be given on the same day or separated by at least four weeks , because the immune response to the first can blunt the second.
Catch-Up and Documentation
For a patient with an incomplete or missing record, the principle is " the series does not restart " — resume from where it stopped, using minimum intervals rather than routine intervals to complete it efficiently. Verify records from the provincial registry, the previous provider, or the patient's own card. Undocumented vaccination is treated as not given, though serology is an option for some antigens such as hepatitis B and measles. Record every administration with the product, lot number, expiry, dose, site, route, date, and administrator, and report it to the provincial registry where required.
The Travel Health Consultation
Ideally conducted at least six weeks before departure , allowing time for multi-dose series and for immunity to develop.
Assess: exact destinations including rural or urban, dates and duration, style of travel and accommodation, planned activities such as trekking or animal contact, altitude, health status and pregnancy, current medications, and immunization history.
- Category Examples
- Routine to update Measles-mumps-rubella, tetanus-diphtheria-pertussis, polio, influenza, COVID-19
- Commonly recommended Hepatitis A, hepatitis B, typhoid
- Destination-specific Yellow fever, Japanese encephalitis, rabies pre-exposure, meningococcal quadrivalent
- Required for entry Yellow fever for certain countries; meningococcal for Hajj pilgrimage
Yellow fever vaccine may only be administered at a designated yellow fever vaccination centre , which issues the International Certificate of Vaccination or Prophylaxis; the certificate becomes valid 10 days after vaccination.
Malaria prevention
Prevention rests first on bite avoidance: an insect repellent containing DEET or icaridin, permethrin-treated clothing, insecticide-treated bed nets, and covering skin at dusk and dawn.
Agent Dosing Key points
Atovaquone-proguanil Daily; start 1 to 2 days before, continue 7 days after leaving Well tolerated; take with food or a milky drink
Doxycycline Daily; start 1 to 2 days before, continue 4 weeks after Photosensitivity, esophagitis — take upright with water; avoid in pregnancy and in children under 8
Mefloquine Weekly; start 2 to 3 weeks before, continue 4 weeks after Avoid with a history of psychiatric or seizure disorder
Chloroquine Weekly Only for the few remaining chloroquine-sensitive areas
Emphasise that no prophylaxis is fully protective , and that any fever during travel or within a year of return must be assessed urgently for malaria.
Traveller's diarrhea and other advice
Advise safe food and water practices, and provide oral rehydration salts. Loperamide is appropriate for mild non-bloody diarrhea without fever. Standby antibiotic therapy may be supplied for moderate to severe illness, chosen with local resistance in mind; azithromycin is preferred in South and Southeast Asia because of fluoroquinolone resistance. Counsel additionally on venous thromboembolism prevention on long flights, altitude illness where relevant, sun protection, and the practical rule of carrying medicines in hand luggage in original labelled containers with a copy of the prescription.